Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies
Sun, Bin, Sengupta, Nilanjan, Rao, Anita, Donnelly, Charles, Waichale, Vinit, Roy, Arnab Sinha, Ramaswamy, Shilpa, Pathak, Divya, Bowsher, Ronald R, Raiter, Yaron, Aubonnet, Patrick, Barve, Abhijit
Published in BMC endocrine disorders (26.06.2021)
Published in BMC endocrine disorders (26.06.2021)
Get full text
Journal Article
Visually evoked cerebral vasomotor response in smoking and nonsmoking young adults, investigated by functional transcranial Doppler
Oláh, László, Raiter, Yaron, Candale, Claudia, Molnár, Sándor, Rosengarten, Bernhard, Bornstein, Natan M, Csiba, László
Published in Nicotine & tobacco research (01.02.2008)
Published in Nicotine & tobacco research (01.02.2008)
Get more information
Journal Article
729-P: Efficacy and Safety of Mylan Insulin Glargine Products (MYL-1501D) from Two Manufacturing Processes (Process V and Process VI) in Combination with Insulin Lispro in Subjects with Type 1 Diabetes Mellitus
RAITER, YARON, BLEVINS, THOMAS, SUN, BIN, CHULLIKANA, ANOOP, RANGANNA, GOPINATH, BARVE, ABHIJIT
Published in Diabetes (New York, N.Y.) (01.06.2021)
Published in Diabetes (New York, N.Y.) (01.06.2021)
Get full text
Journal Article
Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study
Blevins, Thomas C., Barve, Abhijit, Raiter, Yaron, Aubonnet, Patrick, Athalye, Sandeep, Sun, Bin, Muniz, Rafael
Published in Diabetes, obesity & metabolism (01.03.2020)
Published in Diabetes, obesity & metabolism (01.03.2020)
Get full text
Journal Article
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication Study
Findling, Robert L, Atkinson, Sarah, Bachinsky, Mary, Raiter, Yaron, Abreu, Paula, Ianos, Claudia, Chappell, Phillip
Published in Journal of child and adolescent psychopharmacology (01.04.2022)
Published in Journal of child and adolescent psychopharmacology (01.04.2022)
Get more information
Journal Article
Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study
Blevins, Thomas C., Barve, Abhijit, Sun, Bin, Raiter, Yaron, Aubonnet, Patrick, Muniz, Rafael, Athalye, Sandeep, Ankersen, Michael
Published in Diabetes, obesity & metabolism (01.01.2019)
Published in Diabetes, obesity & metabolism (01.01.2019)
Get full text
Journal Article
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)
Atkinson, Sarah, Bachinsky, Mary, Raiter, Yaron, Abreu, Paula, Ianos, Claudia, Chappell, Phillip, Findling, Robert L
Published in Journal of child and adolescent psychopharmacology (01.10.2022)
Published in Journal of child and adolescent psychopharmacology (01.10.2022)
Get more information
Journal Article
728-P: Mylan Insulin Aspart (MYL-1601D) Is Bioequivalent to Novolog (U.S.-Licensed Insulin Aspart) and NovoRapid (EU-Approved Insulin Aspart)
RAITER, YARON, HÖVELMANN, ULRIKE, CHULLIKANA, ANOOP, LIU, MARK, DONNELLY, CHARLES M., LAWRENCE, TRACEY, SENGUPTA, NILANJAN, RANGANNA, GOPINATH, BARVE, ABHIJIT, C.L., GOPU
Published in Diabetes (New York, N.Y.) (01.06.2021)
Published in Diabetes (New York, N.Y.) (01.06.2021)
Get full text
Journal Article
741-P: Efficacy and Safety of MYL-1601D (Mylan's Insulin Aspart) Compared with Novolog (Novo Nordisk's Insulin Aspart) in Patients with Type 1 Diabetes (T1DM) after 24 Weeks
RAITER, YARON, BLEVINS, THOMAS, SUN, BIN, DONNELLY, CHARLES M., RAO, ANITA U., SHAPIRO, ROXANN, VASHISHTA, LAXMIKANT, RANGANNA, GOPINATH, CHULLIKANA, ANOOP, BARVE, ABHIJIT
Published in Diabetes (New York, N.Y.) (01.06.2021)
Published in Diabetes (New York, N.Y.) (01.06.2021)
Get full text
Journal Article
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study
Blevins, Thomas C., Raiter, Yaron, Sun, Bin, Donnelly, Charles, Shapiro, Roxann, Chullikana, Anoop, Rao, Anita, Vashishta, Laxmikant, Ranganna, Gopinath, Barve, Abhijit
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.11.2022)
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.11.2022)
Get full text
Journal Article
Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
Hövelmann, Ulrike, Raiter, Yaron, Chullikana, Anoop, Liu, Mark, Donnelly, Charles, Lawrence, Tracey, Sengupta, Nilanjan, CL, Gopu, Ranganna, Gopinath, Barve, Abhijit
Published in Diabetes, obesity & metabolism (01.12.2021)
Published in Diabetes, obesity & metabolism (01.12.2021)
Get full text
Journal Article
Primary triage, evacuation priorities, and rapid primary distribution between adjacent hospitals--lessons learned from a suicide bomber attack in downtown Tel-Aviv
Pinkert, Moshe, Lehavi, Ofer, Goren, Odeda Benin, Raiter, Yaron, Shamis, Ari, Priel, Zvi, Schwartz, Dagan, Goldberg, Avishay, Levi, Yehezkel, Bar-Dayan, Yaron
Published in Prehospital and disaster medicine (01.08.2008)
Published in Prehospital and disaster medicine (01.08.2008)
Get more information
Journal Article